Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel Free MOR Stock Alerts

MorphoSys (MOR) Competitors

MorphoSys logo
$18.96 0.00 (0.00%)
As of 08/13/2026
Compare

MOR vs. ELAN, AXSM, RDY, CRNX, and ALKS

Should you buy MorphoSys stock or one of its competitors? MorphoSys's main competitors and comparable companies include Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), Crinetics Pharmaceuticals (CRNX), and Alkermes (ALKS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MorphoSys compare to Elanco Animal Health?

MorphoSys (NASDAQ:MOR) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Elanco Animal Health has a consensus price target of $29.09, suggesting a potential upside of 25.31%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than MorphoSys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MorphoSys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Elanco Animal Health
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77

Elanco Animal Health has a net margin of -3.96% compared to MorphoSys' net margin of -226.79%. Elanco Animal Health's return on equity of 8.13% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
MorphoSys-226.79% -694.31% -22.55%
Elanco Animal Health -3.96%8.13%3.99%

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MorphoSys has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$238.28M11.99-$205.35M-$3.48N/A
Elanco Animal Health$4.72B2.46-$232M-$0.41N/A

MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

In the previous week, Elanco Animal Health had 24 more articles in the media than MorphoSys. MarketBeat recorded 24 mentions for Elanco Animal Health and 0 mentions for MorphoSys. Elanco Animal Health's average media sentiment score of 0.85 beat MorphoSys' score of 0.00 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company Overall Sentiment
MorphoSys Neutral
Elanco Animal Health Positive

Summary

Elanco Animal Health beats MorphoSys on 14 of the 17 factors compared between the two stocks.

How does MorphoSys compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Axsome Therapeutics has a net margin of -24.68% compared to MorphoSys' net margin of -226.79%. Axsome Therapeutics' return on equity of -275.76% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
Axsome Therapeutics-24.68% -275.76% -28.82%
MorphoSys -226.79%-694.31%-22.55%

Axsome Therapeutics has higher revenue and earnings than MorphoSys. Axsome Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome Therapeutics$638.50M17.60-$183.17M-$3.75N/A
MorphoSys$238.28M11.99-$205.35M-$3.48N/A

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Axsome Therapeutics currently has a consensus price target of $267.60, indicating a potential upside of 24.70%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than MorphoSys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics
2 Sell rating(s)
2 Hold rating(s)
16 Buy rating(s)
2 Strong Buy rating(s)
2.82
MorphoSys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Axsome Therapeutics had 30 more articles in the media than MorphoSys. MarketBeat recorded 30 mentions for Axsome Therapeutics and 0 mentions for MorphoSys. Axsome Therapeutics' average media sentiment score of 0.45 beat MorphoSys' score of 0.00 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Axsome Therapeutics Neutral
MorphoSys Neutral

Axsome Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Summary

Axsome Therapeutics beats MorphoSys on 13 of the 17 factors compared between the two stocks.

How does MorphoSys compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Dr. Reddy's Laboratories had 17 more articles in the media than MorphoSys. MarketBeat recorded 17 mentions for Dr. Reddy's Laboratories and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 beat Dr. Reddy's Laboratories' score of -0.27 indicating that MorphoSys is being referred to more favorably in the news media.

Company Overall Sentiment
Dr. Reddy's Laboratories Neutral
MorphoSys Neutral

Dr. Reddy's Laboratories has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$3.58B2.86$456M$0.4427.85
MorphoSys$238.28M11.99-$205.35M-$3.48N/A

Dr. Reddy's Laboratories has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to MorphoSys' net margin of -226.79%. Dr. Reddy's Laboratories' return on equity of 9.49% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Reddy's Laboratories10.15% 9.49% 6.32%
MorphoSys -226.79%-694.31%-22.55%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Reddy's Laboratories
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
MorphoSys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Dr. Reddy's Laboratories beats MorphoSys on 10 of the 14 factors compared between the two stocks.

How does MorphoSys compare to Crinetics Pharmaceuticals?

MorphoSys (NASDAQ:MOR) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

MorphoSys has a net margin of -226.79% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Crinetics Pharmaceuticals' return on equity of -44.22% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
MorphoSys-226.79% -694.31% -22.55%
Crinetics Pharmaceuticals -1,189.88%-44.22%-39.77%

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Crinetics Pharmaceuticals has a consensus target price of $81.00, indicating a potential downside of 4.31%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Crinetics Pharmaceuticals is more favorable than MorphoSys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MorphoSys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Crinetics Pharmaceuticals
1 Sell rating(s)
11 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.24

In the previous week, Crinetics Pharmaceuticals had 5 more articles in the media than MorphoSys. MarketBeat recorded 5 mentions for Crinetics Pharmaceuticals and 0 mentions for MorphoSys. Crinetics Pharmaceuticals' average media sentiment score of 1.30 beat MorphoSys' score of 0.00 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
MorphoSys Neutral
Crinetics Pharmaceuticals Positive

MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, suggesting that its share price is 88% less volatile than the broader market.

MorphoSys has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$238.28M11.99-$205.35M-$3.48N/A
Crinetics Pharmaceuticals$7.70M1,166.08-$465.32M-$5.04N/A

Summary

Crinetics Pharmaceuticals beats MorphoSys on 9 of the 16 factors compared between the two stocks.

How does MorphoSys compare to Alkermes?

MorphoSys (NASDAQ:MOR) and Alkermes (NASDAQ:ALKS) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 4.6% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Alkermes has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$238.28M11.99-$205.35M-$3.48N/A
Alkermes$1.48B5.60$241.66M$0.38129.76

Alkermes has a net margin of 3.96% compared to MorphoSys' net margin of -226.79%. Alkermes' return on equity of 4.15% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
MorphoSys-226.79% -694.31% -22.55%
Alkermes 3.96%4.15%2.19%

In the previous week, Alkermes had 10 more articles in the media than MorphoSys. MarketBeat recorded 10 mentions for Alkermes and 0 mentions for MorphoSys. Alkermes' average media sentiment score of 1.49 beat MorphoSys' score of 0.00 indicating that Alkermes is being referred to more favorably in the news media.

Company Overall Sentiment
MorphoSys Neutral
Alkermes Positive

Alkermes has a consensus price target of $54.56, suggesting a potential upside of 10.65%. Given Alkermes' stronger consensus rating and higher possible upside, analysts plainly believe Alkermes is more favorable than MorphoSys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MorphoSys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Alkermes
1 Sell rating(s)
4 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.72

Summary

Alkermes beats MorphoSys on 15 of the 17 factors compared between the two stocks.

Get MorphoSys News Delivered to You Automatically

Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MOR vs. The Competition

Export
MetricMorphoSysPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.86B$11.72B$6.98B$13.03B
Dividend YieldN/A2.70%2.58%10.72%
P/E Ratio-5.45783.86269.5625.24
Price / Sales11.99748.12596.34100.74
Price / CashN/A67.4570.5350.75
Price / Book54.1710.7413.026.32
Net Income-$205.35M$2.78B$3.45B$347.92M
7 Day PerformanceN/A-0.29%0.69%0.91%
1 Month PerformanceN/A-0.17%1.32%0.89%
1 Year PerformanceN/A160.95%66.86%20.28%

MorphoSys Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MOR
MorphoSys
N/A$18.96
flat		N/AN/A$2.86B$238.28MN/A730
ELAN
Elanco Animal Health
4.3645 of 5 stars		$22.10
-2.8%		$29.09
+31.6%		+26.3%$11.36B$4.72BN/A9,400
AXSM
Axsome Therapeutics
3.3143 of 5 stars		$214.66
-0.5%		$267.60
+24.7%		+95.3%$11.30B$638.50MN/A380
RDY
Dr. Reddy's Laboratories
2.1095 of 5 stars		$12.41
-0.3%		N/A-12.9%$10.39B$3.58B28.2127,527
CRNX
Crinetics Pharmaceuticals
1.9518 of 5 stars		$84.46
+0.1%		$81.00
-4.1%		+180.6%$8.95B$7.70MN/A210

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MOR) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
The options guide that actually starts at the beginning
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel